US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed
Name
/
Code
Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date
Listing Date
REFIRE
02570.HK
Electrical Components & Equipment 145-165 20 3,333 2024/12/03 2024/12/05 2024/12/06
Dmall
02586.HK
Application Software 30.21 100 N/A 2024/12/03 2024/12/05 2024/12/06
Summary
We are a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. Our mission is to improve the lives of valvular heart disease patients by providing optimal and affordable medical solutions through continuous innovation.

Our self-developed first-generation transcatheter aortic valve implantation (“TAVI”) product, VitaFlowTM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. As of the Latest Practicable Date, there were five approved or commercialized TAVI products in China, among which, VitaFlowTM is the first one utilizing bovine pericardium as valve tissue, according to Frost & Sullivan. Generally, bovine materials provide better durability and hemodynamic performance as compared to porcine materials. VitaFlowTM also innovatively features a first-in-China double-layer polyethylene terephthalate (“PET”) skirt and the only marketed motorized delivery system worldwide, according to Frost & Sullivan. These unique designs have enabled VitaFlowTM to achieve potentially best-in-class clinical trial results among TAVI products in China, including a low all-cause mortality rate and low incidences of postoperative complications. For details, see “Industry Overview— Competitive Landscape—TAVI Market.” We also launched our first generation in-house developed AlwideTM balloon catheter and AlpassTM catheter sheath as part of the VitaFlowTM offering, making us the only medical device company in China that has a comprehensive offering of in-house developed complementary TAVI procedural accessories, according to Frost & Sullivan. Our second-generation TAVI product, VitaFlowTM II, has completed the Registration Clinical Trial in China and is also under clinical trial in Europe. We submitted the registration application for VitaFlowTM II to the NMPA in October 2020. The application was accepted by the NMPA in November 2020 and is currently under review. We currently expect that we will complete the registration of VitaFlowTM II in China by the end of 2021. In addition, we plan to apply for the CE Mark of VitaFlowTM II by the end of 2021. According to Frost & Sullivan, as of the Latest Practicable Date, VitaFlowTM II was the only TAVI product developed in China that had commenced a clinical trial in Europe. In addition to our TAVI products, we currently have five transcatheter mitral valve (“TMV”) pipeline products strategically targeting all mainstream viable transcatheter valve therapy (“TVT”) options for mitral regurgitation through in- house development and collaboration with our global partners, namely 4C Medical and ValCare, each being a medical device company focusing on the R&D of mitral and tricuspid valve medical devices, enabling us to penetrate the vast but underserved TMV market.

We are deeply rooted in the vast, rapid-growing and substantially underpenetrated heart valve medical device market. According to Frost & Sullivan, in 2019, approximately 213.2 million patients worldwide suffered from valvular heart disease, which led to 2.6 million deaths. In recent years, transcatheter valve therapy has gradually replaced traditional open-chest surgeries to treat patients with valvular heart diseases in light of its advantages such as less surgical risks, minor trauma and shorter hospitalization time and postoperative recovery period. Our product portfolio strategically focuses on addressing the most prevalent aortic valve and mitral valve diseases, including aortic stenosis and mitral regurgitation.

‧ Aortic stenosis. According to Frost & Sullivan, patients suffering from aortic stenosis globally is expected to grow at a CAGR of 14.3% from 19.7 million in 2019 to 22.1 million in 2025. As a result, the global TAVI market size is expected to increase at a CAGR of 12.9% from US$4.8 billion (or RMB32.3 billion) in 2019 to US$10.0 billion (or RMB67.3 billion) in 2025. Compared to the TAVI market in developed countries, such as the United States, China's TAVI market is significantly under-penetrated. In 2019, there were approximately 2,400 TAVI procedures performed in China with a penetration rate of 0.3%, as compared to approximately 66,800 TAVI procedures performed and a penetration rate of 23.4% in the U.S. It is expected that in 2025 there will be approximately 42,000 TAVI procedures performed in China, representing a CAGR of 60.7% for the next five years and a penetration rate of 4.5% in 2025. It is expected that China's TAVI market will grow from RMB392.0 million in 2019 to RMB5,055.7 million in 2025 at a CAGR of 53.1%.

‧ Mitral regurgitation. In 2019, there were 96.7 million patients worldwide and 10.6 million patients in China suffering from mitral regurgitation. Due to the complexity of TMV therapy, global TMV market is still in a relatively early stage with only six approved TMV repair products and one approved TMV replacement product globally. Most of the existing TMV technologies have certain clinical limitations, such as causing obstructions on the left ventricular outflow tract (“LVOT”), impairing function on the left ventricle and leading to device embolization. As a result, we believe the TMV products that can address these clinical limitations will benefit the most from the vast but unmet medical demands in this area. According to Frost & Sullivan, driven by the increasing market demands of TMV repair/replacement products and emerging innovative TMV technologies, global TMV market is expected to reach US$17.4 billion (or RMB117.0 billion) by 2030 and will eventually grow to three or four times of the global TAVI market.

We have developed a medical device platform focusing on valvular heart disease. The platform covers our four key business functions, namely R&D, clinical trial, manufacturing and commercialization. Leveraging this platform, all the key business functions are integrated to enable smooth collaboration during the whole life-cycle of a product candidate to speed up the product development process in a cost-effective manner. The platform lays a solid foundation and builds the strategic moat for our research, development and commercialization competitiveness. Driven by strong innovation capabilities and supported by stringent quality controls, our platform primarily focuses on (i) technological innovation, product design and biological material processing technique; (ii) efficient design and execution of clinical trials; and (iii) manufacturing efficiency. This platform has enabled us to continuously expand our product portfolio to tackle valvular heart diseases with innovative treatment methods. We have also established a quality control system in accordance with GMP standards required by the NMPA and ISO13485:2016.

We have a proven track record of product commercialization. As of July 31, 2020, we had sold 872 units of VitaFlowTM—an average of over 70 units per month in the first year of its commercialization. As of the Latest Practicable Date, TAVI procedures using VitaFlowTM had been performed at over 120 hospitals in China, most of which are Class IIIA Hospitals located at tier-one and tier-two cities, including 18 of the Top 20 TAVI Hospitals. We have established a dedicated in-house sales and marketing team with professional medical background, primarily focusing on academic promotions. Supported by the potentially best-in-class clinical trial results of VitaFlow with respect to all-cause mortality rate and postoperative complications including moderate/severe PVL, major stroke and vascular complications, the patient-oriented pricing strategy, collaborations with KOLs and hospitals, our enabling distributor network and the brand recognition of “MicroPort” in the cardiology field, we believe we are well-positioned to benefit from the rapid growth of China's TAVI market and to further gain market share.

Complemented by our proven commercialization capabilities, medical device platform focusing on valvular heart disease and experienced management team with continuous support from Shareholders, we have successfully developed and launched a TAVI product with potentially best-in- class clinical trial results with respect to all-cause mortality rate and postoperative complications including moderate/severe PVL, major stroke and vascular complications in China and we are also developing our second-generation TAVI product, which is at near-commercialization stage. We are also dedicated to serving the vast but underserved TMV market, strategically targeting all mainstream viable TVT options for mitral regurgitation through in-house development and collaboration with our global partners, namely 4C Medical and ValCare, each being a medical device company focusing on the R&D of mitral and tricuspid valve medical devices. We believe these competitive strengths are difficult to replicate and we are well-positioned to capture the tremendous growth potential of the valvular heart disease market. At the same time, we plan to continue to strengthen our presence in China's TAVI market, advance our international strategy, rapidly advance our TMV pipeline and other product candidates and improve operational efficiency and achieve economies of scale to support long-term growth.

Source: CardioFlow-B (02160) Prospectus (IPO Date : 2021/01/26)
Listing Market MAIN
Industry Biotechnology
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders [00853] MicroPort Scientific Corporation (46.13%)
[03908] China International Capital Corporation Limited (7.53%)
Directors Chen Guoming (Chairman and Non-Executive Director)
Zhao Liang (Senior Vice President and Executive Director)
Yan Luying (Vice President and Executive Director)
Jeffrey R Lindstrom (Executive Director)
Wu Xia (Non-Executive Director)
Zhang Junjie (Non-Executive Director)
Jonathan H. Chou (Independent Non-Executive Director)
Sun Zhixiang (Independent Non-Executive Director)
Ding Jiandong (Independent Non-Executive Director)
Company Secretary Chan Lok Yee
Li Xiangmei
Principal Bankers Shanghai Pudong Development Bank Co., Ltd.
Solicitors Kirkland & Ellis International
Auditors KPMG
Registered Office Room 1901, 19th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong
Share Registrars Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No (852) 2862-8628
Internet Address http://www.cardioflowmedtech.com
Email Address [email protected]
Tel No (86 21) 3895-4600
Fax No (86 21) 5080-1305
 
SITEMAP
Email: [email protected]
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.